

USFDA grants EUA to Novavax COVID-19 vaccine for adolescents

22 August 2022 | News

Novavax' vaccine is the first protein-based COVID-19 vaccine authorised in the US



Novavax has announced that its COVID-19 vaccine, Adjuvanted (NVX-CoV2373) has received expanded emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) to provide a two-dose primary series for active immunisation to prevent COVID-19 in adolescents aged 12 through 17.

"Having more vaccine options for use in both adults and adolescents, like the Novavax COVID-19 Vaccine, Adjuvanted will hopefully help increase vaccination rates, particularly as we prepare for ongoing surges of COVID-19 with the start of fall and the back-to-school season," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "We hope that our vaccine, developed using an innovative approach to recombinant protein vaccine technology, may have a special role in adolescent vaccination based on parents' and caregivers' familiarity with protein-based vaccines used in other disease areas."

The next step for the vaccine is a policy recommendation for use from the Centers for Disease Control and Prevention (CDC). Doses of the Novavax COVID-19 Vaccine, Adjuvanted are available for use in adolescents upon the CDC's recommendation.

In July 2022 the US FDA had granted EUA for a two-dose primary series in adults aged 18 and older, followed by a recommendation from the CDC Advisory Committee on Immunization Practices, and endorsement from the CDC.